Synaptogenix (TAOX) Stock Price, News & Analysis

Company Overview

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.

Key Stats

• Today's Range: $6.85 to $8.10
• 50-Day Range: $5.47 to $9.56
• 52-Week Range: $1.84 to $11.98
• Volume: 541,345 shs
• Average Volume: 397,155 shs
• Market Capitalization: $24.05 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Synaptogenix Stock Analysis - MarketRank™

Synaptogenix scored higher than 4% of companies evaluated by MarketBeat, and ranked 21st out of 21 stocks in the manufacturing sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Synaptogenix.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Synaptogenix is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Synaptogenix is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Synaptogenix has a P/B Ratio of 1.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.60% of the float of Synaptogenix has been sold short.

Short Interest Ratio / Days to Cover

Synaptogenix has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Synaptogenix has recently increased by 0.95%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Synaptogenix does not currently pay a dividend.

Dividend Growth

Synaptogenix does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

17.60% of the float of Synaptogenix has been sold short.

Short Interest Ratio / Days to Cover

Synaptogenix has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Synaptogenix has recently increased by 0.95%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.63

News Sentiment

Synaptogenix has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.39 average news sentiment score of Manufacturing companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Synaptogenix this week, compared to 1 article on an average week.

Search Interest

5 people have searched for TAOX on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.

MarketBeat Follows

2 people have added Synaptogenix to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Synaptogenix insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.73% of the stock of Synaptogenix is held by insiders.

Percentage Held by Institutions

Only 10.34% of the stock of Synaptogenix is held by institutions.

TAOX Stock Analysis - Frequently Asked Questions

How have TAOX shares performed this year?

Synaptogenix's stock was trading at $8.41 at the beginning of the year. Since then, TAOX shares have decreased by 18.1% and is now trading at $6.89.

How were Synaptogenix's earnings last quarter?

Synaptogenix, Inc. (NASDAQ:TAOX) issued its quarterly earnings results on Friday, August, 15th. The company reported ($11.26) EPS for the quarter.

How do I buy shares of Synaptogenix?

Shares of TAOX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/15/2025
• Today: 10/10/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Manufacturing
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TAOX
• CIK: 1571934
• Web: N/A
• Phone: (973) 242-0005
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($20.16)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$12.77 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -277.76%
• Return on Assets: -150.79%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 20.52
• Quick Ratio: 20.52

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.33 per share
• Price / Book: 1.65

Miscellaneous

• Outstanding Shares: 3,490,000
• Free Float: 3,392,000
• Market Cap: $24.95 million
• Optionable: N/A
• Beta: 1.89